{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T11:00:22Z","timestamp":1776078022900,"version":"3.50.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2019,5,15]],"date-time":"2019-05-15T00:00:00Z","timestamp":1557878400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,5,15]],"date-time":"2019-05-15T00:00:00Z","timestamp":1557878400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004416","name":"Vlaamse Liga Tegen Kanker","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004416","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Wetenschappelijk Fonds Willy Gepts"},{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005026","name":"Stichting Tegen Kanker","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005026","id-type":"DOI","asserted-by":"publisher"}]},{"name":"SRP-VUB"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1038\/s41416-019-0471-0","type":"journal-article","created":{"date-parts":[[2019,5,14]],"date-time":"2019-05-14T23:16:51Z","timestamp":1557875811000},"page":"1137-1146","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["The anaphase-promoting complex\/cyclosome: a new promising target in diffuse large B-cell lymphoma and mantle cell lymphoma"],"prefix":"10.1038","volume":"120","author":[{"given":"Anke","family":"Maes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Maes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hendrik","family":"De Raeve","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"De Smedt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip","family":"Vlummens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanessa","family":"Szablewski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Devin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvia","family":"Faict","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kim","family":"De Veirman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eline","family":"Menu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fritz","family":"Offner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcel","family":"Spaargaren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00e9r\u00f4me","family":"Moreaux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karin","family":"Vanderkerken","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Els","family":"Van Valckenborgh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elke","family":"De Bruyne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,5,15]]},"reference":[{"key":"471_CR1","doi-asserted-by":"publisher","first-page":"s125","DOI":"10.7861\/clinmedicine.16-6-s125","volume":"16","author":"T Cummin","year":"2016","unstructured":"Cummin, T. & Johnson, P. Lymphoma: turning biology into cures. Clin. Med (North. Il). 16, s125\u20139 (2016).","journal-title":"Clin. Med (North. Il)."},{"key":"471_CR2","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1177\/2040620717719616","volume":"8","author":"B Fakhri","year":"2017","unstructured":"Fakhri, B. & Hahl, B. Current and emerging treatment options for mantle cell lymphoma. Ther. Adv. Hematol. 8, 223\u2013234 (2017).","journal-title":"Ther. Adv. Hematol."},{"key":"471_CR3","doi-asserted-by":"publisher","first-page":"79","DOI":"10.3960\/jslrt.56.79","volume":"56","author":"K Miyazaki","year":"2016","unstructured":"Miyazaki, K. Treatment of diffuse large b-cell lymphoma. J. Clin. Exp. Hematop. 56, 79\u201388 (2016).","journal-title":"J. Clin. Exp. Hematop."},{"key":"471_CR4","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/S0140-6736(12)60605-9","volume":"380","author":"KR Shankland","year":"2012","unstructured":"Shankland, K. R., Armitage, J. O. & Hancock, B. W. Non-Hodgkin lymphoma. Lancet 380, 848\u2013857 (2012).","journal-title":"Lancet"},{"key":"471_CR5","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.2174\/1568026617666170104145640","volume":"17","author":"AD Tangutur","year":"2017","unstructured":"Tangutur, A. D., Kumar, D., Krishna, K. V. & Kantevari, S. Microtubule targeting agents as cancer chemotherapeutics: an overview of molecular hybrids as stabilizing and destabilizing agents. Curr. Top. Med Chem. 17, 2523\u20132537 (2017).","journal-title":"Curr. Top. Med Chem."},{"key":"471_CR6","unstructured":"U.S. National Institutes of Health\u2014ClinicalTrials.gov. \n                    www.clinicaltrials.gov\n                    \n                  ."},{"key":"471_CR7","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s10637-013-0050-9","volume":"32","author":"K Kelly","year":"2014","unstructured":"Kelly, K., Shea, T., Goy, A., Berdeja, J., Reeder, C., McDonagh, K. et al. Phase 1 study of MLN8237\u2013investigational aurora A kinase inhibitor\u2013in relapsed\/refractory multiple myeloma, non-Hodgkin lymphoma and chronic lymphocytic leukemia. Invest New Drugs 32, 489\u2013499 (2014).","journal-title":"Invest New Drugs"},{"key":"471_CR8","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1182\/blood.V118.21.95.95","volume":"118","author":"J Friedberg","year":"2011","unstructured":"Friedberg, J., Mahadevan, D., Jung, J., Persky, D. O., Lossos, I. S., Danaee, H. et al. Phase 2 trial of alisertib (MLN8237), an investigational, potent inhibitor of aurora A kinase (AAK), in patients (pts) with aggressive B- and T-cell non-hodgkin lymphoma (NHL). Blood 118, 95 (2011).","journal-title":"Blood"},{"key":"471_CR9","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1007\/s10637-013-0018-9","volume":"31","author":"S Dent","year":"2013","unstructured":"Dent, S., Gelmon, K., Chi, K., Jonker, D., Wainman, N., Capier, C. et al. NCIC CTG IND.181: phase 1 study of AT9283 given as a weekly 24\u2009h infusion in advanced malignancies. Invest New Drugs 31, 1522\u20131529 (2013).","journal-title":"Invest New Drugs"},{"key":"471_CR10","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/cdd.2011.197","volume":"19","author":"E Manchado","year":"2012","unstructured":"Manchado, E., Guillamot, M. & Malumbres, M. Killing cells by targeting mitosis. Cell Death Differ. 19, 369\u2013377 (2012).","journal-title":"Cell Death Differ."},{"key":"471_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s13008-016-0021-6","volume":"11","author":"Z Zhou","year":"2016","unstructured":"Zhou, Z., He, M., Shah, A. A. & Wan, Y. Insights into APC\/C: from cellular function to diseases and therapeutics. Cell Div. 11, 9 (2016).","journal-title":"Cell Div."},{"key":"471_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fonc.2011.00060","volume":"1","author":"C Penas","year":"2012","unstructured":"Penas, C., Ramachandran, V. & Ayad, N. G. The APC\/C ubiquitin ligase: from cell biology to tumorigenesis. Front Oncol. 1, 1\u201320 (2012).","journal-title":"Front Oncol."},{"key":"471_CR13","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.pharmthera.2015.04.002","volume":"151","author":"L Wang","year":"2015","unstructured":"Wang, L., Zhang, J., Wan, L., Zhou, X., Wang, Z. & Wei, W. Targeting Cdc20 as a novel cancer therapeutic strategy. Pharm. Ther. 151, 141\u2013151 (2015).","journal-title":"Pharm. Ther."},{"key":"471_CR14","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1038\/sj.onc.1206224","volume":"22","author":"Q Wang","year":"2003","unstructured":"Wang, Q., Moyret-Lalle, C., Couzon, F., Surbiquet-Clippe, C., Saurin, J., Lorca, T. et al. Alterations of anaphase-promoting complex genes in human colon cancer cells. Oncogene 22, 1486\u20131490 (2003).","journal-title":"Oncogene"},{"key":"471_CR15","doi-asserted-by":"crossref","first-page":"4062","DOI":"10.18632\/oncotarget.6768","volume":"7","author":"S Lub","year":"2016","unstructured":"Lub, S., Maes, A., Maes, K., De Veirman, K., De Bruyne, E., Menu, E. et al. Inhibiting the anaphase promoting complex\/cyclosome induces a metaphase arrest and cell death in multiple myeloma cells. Oncotarget 7, 4062\u20134076 (2016).","journal-title":"Oncotarget"},{"key":"471_CR16","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.1038\/bjc.2014.252","volume":"110","author":"H Karra","year":"2014","unstructured":"Karra, H., Repo, H., Ahonen, I., Loyttyniemi, E., Pitkanen, R., Lintunen, M. et al. Cdc20 and securin overexpression predicts short-term breast cancer survival. Br. J. Cancer 110, 2905\u20132913 (2014).","journal-title":"Br. J. Cancer"},{"key":"471_CR17","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1002\/jso.23109","volume":"106","author":"T Kato","year":"2012","unstructured":"Kato, T., Diego, Y., Aragaki, M., Ishikawa, K., Sato, M. & Kaji, M. Overexpression of CDC20 predicts poor prognosis in primary non-small cell lung cancer patients. J. Surg. Oncol. 106, 423\u2013430 (2012).","journal-title":"J. Surg. Oncol."},{"key":"471_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-11-142","volume":"11","author":"W Wu","year":"2013","unstructured":"Wu, W., Hu, K., Wang, D., Zeng, Z., Zhang, D., Chen, D. et al. Cdc20 overexpression predicts a poor prognosis for patients with colorectal cancer. J. Transl. Med. 11, 142 (2013).","journal-title":"J. Transl. Med."},{"key":"471_CR19","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.3892\/ijo.2014.2559","volume":"45","author":"J Li","year":"2014","unstructured":"Li, J., Gao, J., Du, J., Huang, Z. & Wei, L. Increased CDC20 expression is associated with development and progression of hepatocellular carcinoma. Int. J. Oncol. 45, 1547\u20131555 (2014).","journal-title":"Int. J. Oncol."},{"key":"471_CR20","first-page":"722","volume":"7","author":"Z Ding","year":"2014","unstructured":"Ding, Z., Wu, H., Zhang, J., Huang, G. & Ji, D. Expression characteristics of CDC20 in gastric cancer and its correlation with poor prognosis. Int. J. Clin. Exp. Pathol. 7, 722\u2013727 (2014).","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"471_CR21","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/1756-8722-5-15","volume":"5","author":"D Chang","year":"2012","unstructured":"Chang, D., Ma, Y., Ji, B., Liu, Y., Hwu, P., Abbruzzese, J. et al. Increased CDC20 expression is associated with pancreatic ductal adenocercinoma differentiation and prognosis. J. Hematol. Oncol. 5, 15 (2012).","journal-title":"J. Hematol. Oncol."},{"key":"471_CR22","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1038\/sj.onc.1210799","volume":"27","author":"T Kidokoro","year":"2008","unstructured":"Kidokoro, T., Tanikawa, C., Furukawa, Y., Katagiri, T., Nakamura, Y. & Matsuda, K. Cdc20, a potential cancer therapeutic target, is negatively regulated by p53. Oncogene 27, 1562\u20131571 (2008).","journal-title":"Oncogene"},{"key":"471_CR23","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1042\/BST0380065","volume":"38","author":"E Manchado","year":"2010","unstructured":"Manchado, E., Eguren, M. & Malumbres, M. The anaphase-promoting complex\/cyclosome (APC\/C): cell-cycle-dependent and -independent functions. Biochem Soc. Trans. 38, 65\u201371 (2010).","journal-title":"Biochem Soc. Trans."},{"key":"471_CR24","doi-asserted-by":"publisher","first-page":"217","DOI":"10.2353\/ajpath.2008.070957","volume":"173","author":"T Fujita","year":"2008","unstructured":"Fujita, T., Liu, W., Doihara, H. & Wan, Y. Regulation of Skp2-p27 axis by the Cdh1\/anaphase-promoting complex pathway in colorectal tumorigenesis. Am. J. Pathol. 173, 217\u2013228 (2008).","journal-title":"Am. J. Pathol."},{"key":"471_CR25","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1158\/1078-0432.CCR-07-1585","volume":"14","author":"T Fujita","year":"2008","unstructured":"Fujita, T., Liu, W., Doihara, H., Date, H. & Wan, Y. Dissection of the APCCdh1-Skp2 cascade in breast cancer. Clin. Cancer Res. 14, 1966\u20131975 (2008).","journal-title":"Clin. Cancer Res."},{"key":"471_CR26","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.ccr.2010.08.010","volume":"18","author":"X Zeng","year":"2010","unstructured":"Zeng, X., Sigoillot, F., Gaur, S., Choi, S., Pfaff, K. L., Oh, D.-C. et al. Pharmacologic inhibition of the anaphase-promoting complex induces a spindle checkpoint-dependent mitotic arrest in the absence of spindle damage. Cancer Cell. 18, 382\u2013395 (2010).","journal-title":"Cancer Cell."},{"key":"471_CR27","doi-asserted-by":"publisher","first-page":"70481","DOI":"10.18632\/oncotarget.12026","volume":"7","author":"LJ Crawford","year":"2016","unstructured":"Crawford, L. J., Anderson, G., Johnston, C. K. & Irvine, A. E. Identification of the APC\/C co-factor FZR1 as a novel therapeutic target for multiple myeloma. Oncotarget 7, 70481\u201370493 (2016).","journal-title":"Oncotarget"},{"key":"471_CR28","doi-asserted-by":"publisher","first-page":"996","DOI":"10.3324\/haematol.2010.037408","volume":"96","author":"T Cardesa-Salzmann","year":"2011","unstructured":"Cardesa-Salzmann, T., Coloma, L., Gutierrez, G., Chan, W., Weisenburger, D., Climent, F. et al. High microvessel density determines a poor outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus chemotherapy. Haematologica 96, 996\u20131001 (2011).","journal-title":"Haematologica"},{"key":"471_CR29","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1056\/NEJMoa0802885","volume":"359","author":"G Lenz","year":"2008","unstructured":"Lenz, G., Wright, G., Dave, S., Xiao, W., Powell, J., Zhao, H. et al. Stromal gene signatures in large-B-cell lymphomas. N. Engl. J. Med2. 359, 2313\u20132323 (2008).","journal-title":"N. Engl. J. Med2."},{"key":"471_CR30","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1200\/JCO.2014.57.7080","volume":"33","author":"K Dybkaer","year":"2015","unstructured":"Dybkaer, K., Bogsted, M., Falgreen, S., Bodker, J., Kjeldsen, M., Schmitz, A. et al. Diffuse large B-cell lymphoma classification system that associates normal B-cell subset phenotypes with prognosis. J. Clin. Oncol. 33, 1379\u20131388 (2015).","journal-title":"J. Clin. Oncol."},{"key":"471_CR31","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1158\/0008-5472.CAN-09-3419","volume":"70","author":"V Fernandez","year":"2010","unstructured":"Fernandez, V., Salamero, O., Espinet, B., Sol\u00e9, F., Royo, C., Navarro, A. et al. Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma. Cancer Res2. 70, 1408\u20131418 (2010).","journal-title":"Cancer Res2."},{"key":"471_CR32","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/nature11003","volume":"483","author":"J Barretina","year":"2012","unstructured":"Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A., Kim, S. et al. The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483, 603\u2013607 (2012).","journal-title":"Nature"},{"key":"471_CR33","doi-asserted-by":"publisher","first-page":"19079","DOI":"10.18632\/oncotarget.24901","volume":"9","author":"V Szablewski","year":"2018","unstructured":"Szablewski, V., Bret, C., Kassambara, A., Devin, J., Cartron, G., Costes-Martineau, V. et al. An epigenetic regulator-related score (EpiScore) predicts survival in patients with diffuse large B cell lymphoma and identifies patients who may benefit from epigenetic therapy. Oncotarget 9, 19079\u201319099 (2018).","journal-title":"Oncotarget"},{"key":"471_CR34","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/0092-8674(95)90338-0","volume":"81","author":"R King","year":"1995","unstructured":"King, R., Peters, J., Tugendreich, S., Rolfe, M., Hieter, P. & Kirschner, M. A 20S complex containing CDC27 and CDC16 catalyzes the mitosis-specific conjugation of ubiquitin to cyclin B. Cell 81, 279\u2013288 (1995).","journal-title":"Cell"},{"key":"471_CR35","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1128\/MCB.00882-09","volume":"30","author":"D Terrano","year":"2010","unstructured":"Terrano, D., Upreti, M. & Chambers, T. Cyclin-dependent kinase 1-mediated Bcl-xL\/Bcl-2 phosphorylation acts as a functional link coupling mitotic arrest and apoptosis. Mol. Cell Biol. 30, 640\u2013656 (2010).","journal-title":"Mol. Cell Biol."},{"key":"471_CR36","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1038\/nature13660","volume":"514","author":"KL Sackton","year":"2014","unstructured":"Sackton, K. L., Dimova, N., Zeng, X., Tian, W., Zhang, M., Sackton, T. B. et al. Synergistic blockade of mitotic exit by two chemical inhibitors of the APC\/C. Nature 514, 646\u2013649 (2014).","journal-title":"Nature"},{"key":"471_CR37","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1002\/ajh.24797","volume":"92","author":"JM Vose","year":"2017","unstructured":"Vose, J. M. Mantle cell lymphoma: 2017 update on diagnosis, risk-stratification, and clinical management. Am. J. Hematol. 92, 806\u2013813 (2017).","journal-title":"Am. J. Hematol."},{"key":"471_CR38","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1182\/blood.V83.6.1460.1460","volume":"83","author":"TP Miller","year":"1994","unstructured":"Miller, T. P., Grogan, T. M., Dahlberg, S., Spier, C. M., Braziel, R. M., Banks, P. M. et al. Prognostic significance of the Ki-67 - associated proliferative antigen in aggressive non-hodgkin\u2019s lymphomas: a prospective southwest oncology group trial. Blood 83, 1460\u20131466 (1994).","journal-title":"Blood"},{"key":"471_CR39","first-page":"277","volume":"1845","author":"J Zhang","year":"2014","unstructured":"Zhang, J., Wan, L., Dai, X., Sun, Y. & Wei, W. Functional characterization of anaphase promoting complex\/cyclosome (APC\/C) E3 ubiquitin ligases in tumorigenesis. Biochim Biophys. Acta 1845, 277\u2013293 (2014).","journal-title":"Biochim Biophys. Acta"},{"key":"471_CR40","doi-asserted-by":"publisher","unstructured":"Eguren, M., Porlan, E., Manchado, E., Garcia-Higuera, I., Canamero, M., Farinas, I. et al. The APC\/C cofactor Cdh1 prevents replicative stress and p53-dependent cell death in neuronal progenitors. Nat Commun. 4, (2013). \n                    https:\/\/doi.org\/10.1038\/ncomms3880\n                    \n                  .","DOI":"10.1038\/ncomms3880"},{"key":"471_CR41","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1111\/j.1349-7006.2011.01884.x","volume":"102","author":"J Ishizawa","year":"2011","unstructured":"Ishizawa, J., Kuninaka, S., Sugihara, E., Naoe, H., Kobayashi, Y., CHiyoda, T. et al. The cell cycle regulator Cdh1 controls the pool sizes of hematopoietic stem cells and mature lineage progenitors by protecting from genotoxic stress. Cancer Sci. 102, 967\u2013974 (2011).","journal-title":"Cancer Sci."},{"issue":"Suppl","key":"471_CR42","first-page":"S4","volume":"1","author":"J Said","year":"2013","unstructured":"Said, J. Aggressive B-cell lymphomas: how many categories do we need? Mod. Pathol. 1(Suppl), S4, (2013).","journal-title":"Mod. Pathol."},{"key":"471_CR43","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.bcp.2014.06.022","volume":"91","author":"T Das","year":"2014","unstructured":"Das, T., Roy, K., Chakrabarti, T., Mukhopadhyay, S. & Roychoudhury, S. Withaferin A modulates the Spindle assembly checkpoint by degradation of Mad2-Cdc20 complex in colorectal cancer cell lines. Biochem Pharmacol. 91, 31\u201339 (2014).","journal-title":"Biochem Pharmacol."},{"key":"471_CR44","doi-asserted-by":"publisher","first-page":"e34283","DOI":"10.1371\/journal.pone.0034283","volume":"7","author":"J Jiang","year":"2012","unstructured":"Jiang, J., Thyagarajan-Sahu, A., Krchnak, V., Jedinak, A., Sandusky, G. E. & Sliva, D. NAHA, a novel hydroxamic acid-derivative, inhibits growth and angiogenesis of breast cancer in vitro and in vivo. PLoS ONE 7, e34283 (2012).","journal-title":"PLoS One"},{"key":"471_CR45","first-page":"841","volume":"40","author":"Y Gao","year":"2018","unstructured":"Gao, Y., Zhang, B., Wang, Y. & Shang, G. Cdc20 inhibitor apcin inhibits the growth and invasion of osteosarcoma cells. Oncol. Rep. 40, 841\u2013848 (2018).","journal-title":"Oncol. Rep."},{"key":"471_CR46","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1002\/bies.201100094","volume":"33","author":"J Nilsson","year":"2011","unstructured":"Nilsson, J. Cdc20 control of cell fate during prolonged mitotic arrest: do Cdc20 protein levels affect cell fate in response to antimitotic compounds. Bioessays 33, 903\u2013909 (2011).","journal-title":"Bioessays"},{"key":"471_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2013.360","volume":"4","author":"J Eichhorn","year":"2013","unstructured":"Eichhorn, J., Sakurikar, N., Alford, S., Chu, R. & Chambers, T. Critical role of anti-apoptotic Bcl-2 protein phosphorylation in mitotic death. Cell Death Dis. 4, e834 (2013).","journal-title":"Cell Death Dis."},{"key":"471_CR48","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1093\/oxfordjournals.jbchem.a003044","volume":"130","author":"M Shitashige","year":"2001","unstructured":"Shitashige, M., Toi, M., Yano, T., Shibata, M., Matsuo, Y. & Shibasaki, F. Dissociation of Bax from a Bcl-2\/Bax heterodimer triggered by phosphorylation of serine 70 of Bcl-2. J. Biochem. 130, 741\u2013748 (2001).","journal-title":"J. Biochem."},{"key":"471_CR49","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.celrep.2014.01.017","volume":"6","author":"M Eguren","year":"2014","unstructured":"Eguren, M., Alvarez-Fernandez, M., Garcia, F., Lopez-Contreras, A., Fujimitsu, K., Yaguchi, H. et al. A synthetic lethal interaction between APC\/C and topoisomerase poisons uncovered by proteomic screens. Cell Rep. 6, 670\u2013683 (2014).","journal-title":"Cell Rep."},{"key":"471_CR50","doi-asserted-by":"publisher","first-page":"e95184","DOI":"10.1371\/journal.pone.0095184","volume":"9","author":"D Mahadevan","year":"2014","unstructured":"Mahadevan, D., Morales, C., Cooke, L., Manziello, A., Mount, D., Persky, D. et al. Alisertib added to rituximab and vincristine is synthetic lethal and potentially curative in mice with aggressive DLBCL co-overexpressing MYC and BCL2. PLoS ONE 9, e95184 (2014).","journal-title":"PLoS One"},{"key":"471_CR51","doi-asserted-by":"crossref","first-page":"5106","DOI":"10.1182\/blood.V126.23.5106.5106","volume":"126","author":"E Cruz","year":"2015","unstructured":"Cruz, E., Ortiz, J., Garcia-Noblejas, A., Alegre, A. & Saez, R. Liposomal doxorubicin in aggressive B cell lymphoma has similar efficacy to the conventional formulation: results from a retrospective cohort study. Blood 126, 5106 (2015).","journal-title":"Blood"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41416-019-0471-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41416-019-0471-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41416-019-0471-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:04:53Z","timestamp":1684616693000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-019-0471-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,15]]},"references-count":51,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["471"],"URL":"https:\/\/doi.org\/10.1038\/s41416-019-0471-0","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,15]]},"assertion":[{"value":"7 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study protocol was approved by the ethics committee of the university hospital UZ Brussel and informed consent was obtained from all subjects (B.U.N. 143201836541).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"This work was sponsored by the Fonds voor Wetenschappelijk Onderzoek Vlaanderen, Stichting tegen Kanker, Kom Op tegen Kanker, SRP-VUB and Wetenschappelijk Fonds Willy Gepts (UZ Brussel). Ken Maes, Kim De Veirman and Sylvia Faict are (post)doctoral fellows of FWO-Vl.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The datasets supporting the conclusions are included within the article (and its additional files).","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"This work is published under the standard license to publish agreement. After 12 months, the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Note"}}]}}